BioSpace News Archive

Ohana Biosciences, a pioneering reproductive health company that created the world’s first sperm biology product platform, today announced the publication of foundational research conducted by Ohana scientists, unveiling a newly discovered mechanism in sperm biology that creates differences in individual human sperm cells.

Today, the U.S. Food and Drug Administration granted the first conditional approval under its expanded authority to KBroVet-CA1 (potassium bromide chewable tablets) to control seizures in dogs with idiopathic epilepsy. Idiopathic epilepsy is a type of seizure disorder without a known cause

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced registered direct offering of 25,000,000 shares of its common stock.

Ubiquigent Limited (Ubiquigent) and the Mottram Laboratory at the University of York today announced a collaboration to investigate the inhibition of deubiquitylase (DUB) enzymes expressed by the protozoan Leishmania mexicana for the treatment of leishmaniasis

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer.

Adesis, Inc., a leading contract research organization and a wholly-owned subsidiary of Universal Display Corporation, launched its new corporate website in the fourth quarter of 2020 and the site was recognized with a 2020 MarCom Platinum Award.

AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44 per common share, payable March 1, 2021, to stockholders of record at the close of business on February 12, 2021.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that SKIN has published the results of a large registry study finding that the evaluation of genomic atypia using DermTech’s Pigmented Lesion Assay may be a superior approach to guide treatment decisions and manage pigmented lesions, when compared to visual assessment of pigmented lesions.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events

Camber Spine , a leading innovator in spine and medical technologies, has announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its SPIRA ® Lateral 3.0 interbody fusion implant. Part of the SPIRA ® product platform, the SPIRA ® Lateral 3.0 implant is a titanium open architecture LLIF utilizing Camber’s Surface by Design ® technology to optimize